ArticleScience translational medicine2020
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 127 citations in OpenAlex.
- Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1.Cancer discovery · 2026Trial
- Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.Cancer discovery · 2021Trial
- BET Inhibition Synergizes with RLR Signaling to Enhance Tumor Immunogenicity and T-cell Recognition.Cancer immunology research · 2026Article
- Review
- Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.Research square · 2026Article
- Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma.International journal of molecular sciences · 2026Article
- Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants.Biomolecules · 2026Review
- Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.Cancer discovery · 2026Article
- Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Review
- METTL3 Methylation Induces Decay of Endogenous Retroelement Transcripts to Promote Tumor Immune Evasion.Cancer research · 2026Article
- Sustained interferon exposure creates a hyper-metastatic subset of melanoma cells.bioRxiv : the preprint server for biology · 2026Article
- From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma.Journal of personalized medicine · 2026Review
- Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Article
- The IFN-γ response cycle: decoupling tumor killing from evolutionary selection in cancer immunotherapy.Frontiers in immunology · 2026Review
- A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors.Frontiers in immunology · 2026Review
- KDM5B recruits FOXG1 to suppress the IFN response, leading to malignant progression and immune evasion in cervical cancer.Frontiers in medicine · 2026Article
- Antigen processing machinery deficits in head and neck cancers: mechanisms of immune evasion and strategies for therapeutic restoration.Frontiers in oncology · 2026Review
- Traditional and New Views on MSI-H/dMMR Endometrial Cancer.Biomolecules · 2025Review
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 3 countries.
Anusha KalbasiDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA. anushakalbasi@mednet.ucla.edu.ORCID 0000-0001-8692-1457
Mito TariveranmoshabadDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.ORCID 0000-0003-4159-7707
Kevin HakimiDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.ORCID 0000-0002-3067-9128
Sarah KremerDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.ORCID 0000-0001-9563-4986
Katie M CampbellDivision of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.
Juan M FunesDivision of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.
Agustin Vega-CrespoDivision of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.
Giulia ParisiDivision of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0002-2172-3078
Ameya ChampekarDivision of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.
Christine NguyenDepartment of Radiation Oncology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.ORCID 0000-0003-1397-769X
Davis TorrejonDivision of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0002-4864-6236
Daniel ShinDivision of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0002-3784-5336
Jesse M ZaretskyDivision of Hematology-Oncology, Department of Medicine, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0002-4889-2648
Robert D DamoiseauxJonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
Daniel E SpeiserDepartment of Oncology, University of Lausanne, 1015 Lausanne, Switzerland.ORCID 0000-0003-2031-3250
Pedro P Lopez-CasasHighlight Therapeutics, Paterna 46980 (Valencia), Spain.ORCID 0000-0001-9866-7361
Marisol QuinteroHighlight Therapeutics, Paterna 46980 (Valencia), Spain.ORCID 0000-0002-4330-8393
Antoni RibasDivision of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.ORCID 0000-0003-3669-8458
University of California, Los Angeles · USHighlight Therapeutics (Spain) · ESCalifornia NanoSystems Institute · USUniversity of Lausanne · CH
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MVirology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9MThe Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2020 to 2024
$12.8MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LO, ROGER S · 2013 to 2017
$8.4MNCATS NIH HHS KL2 TR001882NCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009120NIAID NIH HHS P30 AI028697
Abstract
Defects in tumor-intrinsic interferon (IFN) signaling result in failure of immune checkpoint blockade (ICB) against cancer, but these tumors may still maintain sensitivity to T cell-based adoptive cell therapy (ACT). We generated models of IFN signaling defects in B16 murine melanoma observed in patients with acquired resistance to ICB. Tumors lacking
Indexed as
Antigen PresentationInterferon-gammaAnimalsHumansImmunotherapyIntracellular Signaling Peptides and ProteinsJanus Kinase 1MiceNF-kappa BSignal TransductionInterferon-gammaIntracellular Signaling Peptides and ProteinsJAK1 protein, humanJanus Kinase 1NF-kappa BNLRC5 protein, humanNLRC5 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.